Lung cancer-targeting conjugate medicine cdGIGPQc-ScFvalphavbeta3

Abstract

The invention discloses a lung cancer-targeting conjugate medicine cdGIGPQc-ScFvalphavbeta3. The lung cancer-targeting conjugate medicine cdGIGPQc-ScFvalphavbeta3 is prepared by coupling a small molecule peptide cdGIGPQc with a single-chain antibody ScFvalphavbeta3 of an integrin alphavbeta3. The lung cancer-targeting conjugate medicine cdGIGPQc-ScFvalphavbeta3 is a small molecule, is capable of easily penetrating through capillary vessels and can be rapidly gathered lung cancer targeting cells; the lung cancer-targeting conjugate medicine has no immunogenicity and allergic risk and has high safety, and an anti-antibody is not generated; and the lung cancer-targeting conjugate medicine can be rapidly cleared in vivo and has no toxic and side effects on the body. The cdGIGPQc-ScFvalphavbeta3 has strong targeting effect on non-small cell lung cancers, small molecule peptide can be specific bound with non-small cell lung cancer cells at any sites in vivo, the treatment effect is not limited by growth sites of tumors, and the cdGIGPQc-ScFvalphavbeta3 is especially suitable for patients suffering from distant organ metastasis type advanced lung cancers.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a coupled drug cdGIGPQc-ScFvαvβ3 targeting lung cancer. Background technique [0002] Lung cancer is one of the most common and deadly malignant tumors in the world, and its incidence rate is also the highest among all malignant tumors. At present, the main treatment mode of lung cancer is multidisciplinary comprehensive treatment, but the overall effect is not satisfactory. Molecular targeted therapy has become one of the important research topics in clinical therapy of lung cancer. [0003] Molecular targeted therapy refers to the design of corresponding therapeutic drugs aimed at the identified carcinogenic site (the site can be a protein molecule or a gene fragment of tumor cells) at the cellular molecular level. The body will specifically select the oncogenic sites to combine with each other to make the tumor cells die specifically, without affecting the normal tissu...

AI Technical Summary

Problems solved by technology

The new monoclonal antibody drug targeting αvβ3 has entered the clinical trial stage. However, due to the large size of the monoclonal antibody molecule, it is difficult to enter the interior of solid tumors; it is slow to clear in the body, easy to produce anti-antibodies, and has many side effects. Therefore, it is easier to develop through the capillary Vascular, small-molecule tumor suppressors capable of entering solid tumor interiors have major implications

Images